M&T Bank’s Ocular Therapeutix OCUL Stock Holding History

M&T Bank’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,698	Closed	-$90.4K	–	1826
2026 Q1	$90.4K	Buy	+10,698	New	+$102K	﹤0.01%	1645

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

M&T Bank's OCUL Position: Q2 2026 in Review

M&T Bank sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 10,698 shares — an estimated $90.4K sold.

M&T Bank first reported a position in OCUL in Q1 2026 and held it in 1 quarter. The position peaked at $90.4K in Q1 2026. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

M&T Bank reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
M&T Bank sold 10,698 Ocular Therapeutix shares in Q2 2026, an estimated $90.4K.
M&T Bank first reported a position in Ocular Therapeutix in Q1 2026 and held it in 1 quarter.
M&T Bank's Ocular Therapeutix position peaked at $90.4K in Q1 2026.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.